Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B

Journal of Viral Hepatitis

Volumn 15, Issue 5, 2008, Pages 392-398

  Gallego, A ^a   Sheldon, J ^b   Garcia Samaniego J ^b   Margall, N ^c   Romero, M ^b   Hornillos, P ^c   Soriano, V ^b   Enriquez J ^a  

^a Gastroenterology Department   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Hospital Sta Creu I St Pau   (Spain)

Author keywords

Adefovir; Initial virological response; Mutations; Resistance; Suboptimal response

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MALE; MUTATION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIROLOGY; VIRUS RESISTANCE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 41549111516     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00966.x     Document Type: Article

References (33)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004 11 : 97 107.
2. Iloeje UH, Yang H, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B virus load. Gastroenterology 2006 130 : 678 686.
3. Chen C, Yang H, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
4. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 125 : 1714 1722.
5. Dienstag J, Goldin R, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 125 : 1714 1722.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 348 : 800 807.
7. Marcellin P, Chang T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 348 : 808 816.
8. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998 28 : 1669 1673.
9. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 : 81 90.
10. Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004 126 : 91 101.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 1751.
12. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003 125 : 292 297.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005 352 : 2673 81.
14. Fung SK, Andreone P, Han SH et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005 43 : 937 943.
15. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006 44 : 283 290.
16. Hézode C, Chevaliez S, Bouvier-Alias M et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol 2007 46 : 791 796.
17. Locarnini S, Hatzakis A, Heathcote EJ et al. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther 2004 9 : 679 693.
18. Locarnini S, Qi X, Arterburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B. J Hepatol 2005 42 (Suppl. 2 17.
19. van Bömmel F, Zöllner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus infection and high HBV-DNA level during adefovir therapy. Hepatology 2006 44 : 318 325.
20. Westland C, Delaney WT, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003 125 : 107 116.
21. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanism, detection and interpretation. J Hepatol 2006 44 : 593 606.
22. Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006 13 : 427 434.
23. Ghany M, Liang J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007 132 : 1574 1585.
24. Schildegen O, Hueseyin S, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006 354 : 1807 1812.
25. Curtis M, Zhu Y, Borroto-Esoda K. HBV rtI233V polymerase variant remains sensitive to adefovir. J Hepatol 2007 46 (Suppl. 1 S27.
26. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006 43 : 1385 1391.
27. Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006 55 : 1488 1495.
28. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HbeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 1419.
29. Rapti I, Dimou E, Panayota M, Hadziyannis J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HbeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 313.
30. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 537.
31. Hoofnagle JH, Doo E, Liang J, Fleischer R, Lok ASF. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007 45 : 1056 1075.
32. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003 39 : 1085 1089.
33. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Klesczewski K, Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006 44 (Suppl. 1 229A.